Tiny molecules may reveal clues about stomach infections in kids
NCT ID NCT07300787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure two molecules, called miRNA-155 and miRNA-204, in stomach tissue from 100 children with ongoing belly pain. The goal is to see if these molecules are linked to gastritis (stomach inflammation) and infection with H. pylori bacteria. Researchers will use special lab tests on biopsy samples to compare molecule levels between infected and uninfected children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: recurrent abdominal pain warranting upper gastrointestinal endoscopy or gastroscopy including * peptic-like dyspepsia (identified by two or more symptoms such as periodic pain, pain relief with food or antacid, pre-meal or hunger-induced pain, nausea/vomiting, and nighttime pain), * dysmotility-like dyspepsia (characterized by abdominal distension, anorexia, weight loss, pain worsening with food/milk, and belching), * and reflux-like dyspepsia (manifesting as heartburn, chest pain exclusion criteria: -patients with gastrointestinal disorders explaining abdominal pain (e.g., inflammatory bowel disease, celiac disease, functional abdominal pain) , -patients on proton pump inhibitors, as well as those with significant medical comorbidities. Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Helicobacter pylori infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Faculty of Medicine Benha University
Banhā, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stomach biopsies could reveal Antibiotic-Resistant h. pylori without extra tests
- Can a Two-Drug combo beat a stubborn stomach bug?
- A 10-Day h. pylori cure? new trial tests a streamlined approach
- Stomach bug tied to belly fat and blood sugar issues?
- New acid reducer shows promise in fighting stomach bug
- New study tests cheaper h. pylori treatment to beat antibiotic resistance